Tukysa was detected in cerebrospinal fluid and plasma of HER2+BC patients
- Why is Lung Cancer High in Non-Smoking Women?
- Is 16-Hour Intermittent Fasting Beneficial for Health?
- Molnupiravir Associated with SARS-CoV-2 Virus Unusual Mutations
- Why Don’t Some Cancer Immunotherapies Always Work as Expected?
- Potential Food Safety Blind Spots in Fast-Food Soda Machines
- Light Therapy Helps Clear Toxic Alzheimer’s Protein from the Brain
Tukysa was detected in cerebrospinal fluid and plasma of HER2+BC patients
- Nearly 300 People Food Poisoning in Japanese 130-Year Restaurant
- FDA’s First Potential TIL Therapy Review Delayed: How to Understand FDA’s “Resource Constraints”?
- A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million
- Nuclear contaminated water: Japanese government paid bribes and corrected the IAEA report
- Top 20 Companies of Instruments and Medical Equipment In The World
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- How long can the patient live after heart stent surgery?
Tukysa was detected in cerebrospinal fluid and plasma of HER2+BC patients.
Tukysa (Tucatinib) and its parent drug ONT-993 have been detected in CSF and are directly proportional to the level in plasma.
The results of a phase 2 study (NCT03501979) examined the combined treatment of tucatinib (Tukysa), trastuzumab (Herceptin) and capecitabine (Xeloda) in HER2-positive breast cancer patients with pial metastases .
The Tukysa+Herceptin+Xeloda combination has been approved by the FDA for the treatment of advanced metastatic HER2-positive breast cancer.
This indication is suitable for patients with or without brain metastases. However, no studies have evaluated the efficacy of this combination in patients with brain metastases. Due to the aggressive nature of the disease, patients with brain metastases are usually excluded from clinical trials.
Pharmacokinetic analysis found that Tukysa (tucatinib) and its parent drug, ONT-993, were detected in the cerebrospinal fluid and were directly proportional to the level in plasma. There are 18 patients in the study, and hopefully it will increase to 30.
The combination therapy of tucatinib, trastuzumab and capecitabine has been approved by the FDA for the treatment of advanced metastatic HER2-positive breast cancer, as well as those diagnosed with brain metastases patient.
But no studies have really evaluated this combination in pia mater disease. In fact, in most clinical trials, leptomeningeal disease is often excluded from research due to its aggressiveness.
In this study, the first 15 patients were evaluated, and the pharmacokinetics in CSL and plasma were evaluated. It was found that Tukysa (Tucatinib) and its parent drug ONT-993 were both detected in CSF and were directly proportional to the level in plasma. This is the first study to evaluate tucatinib and its maternal metabolites in CSF.
Tukysa was detected in cerebrospinal fluid and plasma of HER2+BC patients
(source:internet, reference only)
Disclaimer of medicaltrend.org
